Anxiety research
1Small human studies compared Selank with benzodiazepines.
What does it do?
A tuftsin-derived Russian anxiolytic/nootropic with limited internationally generalizable clinical evidence.
Approved & studied uses
Community uses Reported, unvalidated
Anxiety
13Generalized/social anxiety, PTSD, stress and sleep-related claims.
Cognition
13Memory, learning, focus, neuroprotection and nasal NMDA-related claims.
Immune
13Cytokine, antiviral and inflammatory research.
Reasons people report using it; these do not establish benefit.13
Evidence limits
View research →Robust placebo-controlled effect sizes, long-term safety, and drug interactions.1
5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Limited human safety characterization
FDA states that important human safety information for Selank acetate is lacking.2
No FDA-approved Selank product identified; research formulations are not approved anxiety treatments.
Molecular information
Amino-acid sequence
- Thr
- Lys
- Pro
- Arg
- Pro
- Gly
- Pro
7 residues · N → C3
Length7 amino acids
Molecular weight · Da751.9 Da
Formula, sequence notation & identity
Molecular formulaC33H57N11O93
T–K–P–R–P–G–PSelank: Thr-Lys-Pro-Arg-Pro-Gly-Pro; tuftsin-related heptapeptide.
Free-acid parent peptide. Acetate counterions and N-acetyl derivatives must be distinguished.
Pep-Pedia identity details
7 amino acids · 751.89 Da
Thr-Lys-Pro-Arg-Pro-Gly-ProReference description; checked chemical identity above takes precedence when available.13
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life3 min12
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 15 min
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Russian pharmaceutical data
Source’s reported peak time: 20 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Anxiety signal with limited reporting
The 62-patient comparison described anxiety improvement similar to medazepam and additional anti-fatigue effects; the abstract gives no numerical effect size.1
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 20 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 11 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1604 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| Unspecified | Not specified | Not specified | Anxiety and neurasthenia symptomsHuman study | Not specified | 1 |
Population 62 patients: Selank 30, medazepam 32 Context The indexed abstract omits dosing detail and effect sizes. Route information Not reported in cited source | |||||
| SubQ | 250 mcg daily | Once daily | Mild anxiety reliefReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| SubQ | 250 mcg twice daily | Morning and evening | Moderate anxiety/cognitive enhancementReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| SubQ | 500 mcg daily | Divided doses | Intensive anxiety/stress managementReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| SubQ | 250-350 mcg daily | Morning only | Cognitive enhancement/nootropic useReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| SubQ | 250 mcg twice daily | Consistent timing | PTSD/trauma supportReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| SubQ | 250 mcg daily | Once daily for 2-4 weeks | Immune support during stressReference report | 2-8 weeks, break not required but recommended | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Injectable | |||||
| IntranasalNasal | 300 mcg (1 spray) | Once daily | Mild anxiety/cognitive enhancementReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
| IntranasalNasal | 600 mcg (2 sprays or 1 per nostril) | Once daily | Moderate anxiety reliefReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
| IntranasalNasal | 900 mcg (3 sprays) | Once daily or divided | Intensive anxiety/GAD treatmentReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
| IntranasalNasal | 300-600 mcg | As needed (max 3x daily) | As-needed anxiety reliefReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
| IntranasalNasal | 300 mcg | 30-60 min before cognitive demands | Cognitive enhancement before tasksReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
| IntranasalNasal | 300-600 mcg | During acute episodes | PTSD/trauma episode managementReference report | 2-8 weeks continuous or as-needed use | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 2-8 weeks, break not required but recommended
- Break
- 1-2 weeks between cycles (optional)
Reported timing
Morning for cognitive benefits, evening for anxiety
Nasal
- Use period
- 2-8 weeks continuous or as-needed use
- Break
- 1-2 weeks between cycles (optional)
Reported timing
Morning for cognitive benefits, as-needed for anxiety
Side effects & safety
Limited human safety characterization
FDA states that important human safety information for Selank acetate is lacking.
2Immune-reaction concern
FDA flags aggregation and peptide impurities as possible immunogenicity risks for some routes.
2Formulation gap
Small clinical studies do not establish the long-term safety of injectable research-vial Selank.
12Reported problems
Local/nasal irritation, headache, nausea and unexpected fatigue or mood effects.
Stop symptoms
Allergy, infection/discharge, persistent bleeding/burning, neurological symptoms or worsening anxiety.
Uncertainty
Claims of no dependence, sedation or tolerance are not universal guarantees.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
10 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Benzodiazepines
Caution reportedAdditive sedation possible.13
Reference report · Pep-Pedia label: Use CautionSSRIs
Caution reportedPsychiatric interactions uncertain.13
Reference report · Evidence context: Monitor combinationAlcohol
Avoidance reportedSedation/unpredictable effects.13
Reference report · Pep-Pedia label: Avoid CombinationSemax
Unverified pairingUnproven nootropic stack.13
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingUntested pairing.13
Reference report · Pep-Pedia label: CompatibleNoopept
Unverified pairingUntested pairing.13
Reference report · Pep-Pedia label: CompatiblePhenylpiracetam
Unverified pairingUntested pairing.13
Reference report · Pep-Pedia label: CompatibleModafinil
Unverified pairingUntested pairing.13
Reference report · Pep-Pedia label: CompatiblePhenazepam
Human studyA 70-patient comparative study reported fewer phenazepam adverse effects when Selank was added. It does not establish safety with all benzodiazepines or with research-vial injections.4
Research contextOlanzapine
TheoreticalA cell experiment found altered gene-expression responses with combined exposure. This is not a demonstrated clinical interaction or evidence of safe combination use.5
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
No formulation-specific human reconstitution instructions were verified for this research powder.1
Diluent and storage
A compatible solvent, concentration, preservative and beyond-use period cannot be inferred from vial mass. The cited source does not validate a universal bacteriostatic-water recipe.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The injectable steps name BAC water and refrigerated storage.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- The injection steps state 30 days; the generic nasal banner states 28 days for BAC preparations.
The source describes gentle mixing and avoiding vigorous shaking.
The source mixes route-specific storage claims; a product-specific expiry is not established.
Nasal
Pep-Pedia distinguishes preservative-free saline from BAC water for nasal preparations.
- Solvents mentioned
- Sterile saline / Bacteriostatic water — source alternative
- Reported parameters
- Source-reported intervals: saline, 24–48 hours; BAC water, 28 days; both refrigerated. · It warns that benzyl alcohol in BAC water may irritate nasal tissue.
The source also suggests frozen aliquots; it does not establish validated stability or container compatibility for every nasal formulation.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite to off-white powderReported appearanceClear reconstituted solutionReported appearanceProper labeling and batch informationReported appearanceAppropriate packaging and storageReported concernYellowing, clumping, or moisture exposureReported concernPersistent cloudiness after reconstitutionReported variationUnusual smell or burning sensation
13Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.13
Full storage notes from Pep-Pedia
13Refrigerate 2-8°C, protect from light and heat
Refrigerate 2-8°C, good for 30 days once opened
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Limited human dataSource context
Pep-Pedia conflicts on nasal tolerance versus no tolerance; source compatibility is not safety evidence.
Compound identity & other names
Selank is a synthetic tuftsin analog investigated for anxiety. A small comparative human study suggests a signal, but this is not enough to establish broad psychiatric benefit or the safety of self-prepared injections.
Other names: TP-7 · Selanc · tuftsin analog
No FDA-approved Selank product identified; research formulations are not approved anxiety treatments.
How it may work
Investigated effects involve GABA, monoamines, enkephalins, neurotrophic signaling and cytokines.13
Similar anxiety scores to an active comparator in a small study
A 2008 study assigned 30 patients to Selank and 32 to medazepam for generalized anxiety disorder or neurasthenia. It reported similar anxiolytic effects, plus antiasthenic/psychostimulant effects with Selank. The abstract gives no numerical effect size or placebo comparison.
1Research areas and evidence gaps
Anxiety research. Small human studies compared Selank with benzodiazepines.1
- Robust placebo-controlled effect sizes, long-term safety, and drug interactions.
- A clinically validated subcutaneous dosing schedule; inspected human material concerned intranasal administration.
- Whether modified Selank analogs share the parent compound's effects.
Community reports Unvalidated
PepPedia discusses anxiety relief and cognitive clarity and describes both nasal and injectable use.6
PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations. These injection schedules were not established by the inspected human trial abstract.
Search coverage and review status
No newer controlled clinical trial was verified. Added the checked Selank/olanzapine cell experiment with clinical interaction uncertainty.
- Checked
- 2026-10-12
- Search
- "selank" 2025 2026 study; Selank GABAergic 2017
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Selank for generalized anxiety disorder and neurastheniaAbstract checked
AI-PREPARED SUMMARY
A 62-patient active-comparator study reported similar anxiolysis to medazepam. The English abstract lacks numerical effect sizes and detailed dosing.
Similar anxiety scores to an active comparator in a small study
A 2008 study assigned 30 patients to Selank and 32 to medazepam for generalized anxiety disorder or neurasthenia. It reported similar anxiolytic effects, plus antiasthenic/psychostimulant effects with Selank. The abstract gives no numerical effect size or placebo comparison.
2FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
Regulatory safety assessment.
3PubChem: Selank, CID 11765600Primary source checked
AI-PREPARED SUMMARY
Chemical identity of the seven-residue free-acid peptide, formula C33H57N11O9, molecular weight 751.9 g/mol.
4Medvedev et al.: Selank added to phenazepam in anxiety disordersAbstract checked
AI-PREPARED SUMMARY
Compared phenazepam alone in 30 patients with phenazepam plus Selank in 40; reported earlier symptom change and fewer benzodiazepine adverse effects. Abstract omits dosing details.
5GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 CellsPrimary source checked
AI-PREPARED SUMMARY
Selank alone did not alter measured transcripts in IMR-32 cells; co-treatment changed responses to GABA or olanzapine. Clinical interaction consequences were not tested.
Additional research · Checked 2026-10-12
6PepPedia: reported practices (accessed October 12, 2026)Community source checked
AI-PREPARED SUMMARY
Secondary editorial account of discussed practices; not a clinical trial or representative survey.
7Research catalog: labeled quantitiesCatalog checked
AI-PREPARED SUMMARY
Lists 5 mg and 10 mg configurations. Quantity examples only; vendor quality and suitability are not endorsed.
8GABAergic Neurotransmission Gene Expression (2016)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat neurotransmission-related gene expression changed after Selank; gene effects do not establish freedom from benzodiazepine-like risks in people.
Reported population / model
Rat frontal cortex
Reported study details
300 μg/kg · Real-time PCR analysis
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9BDNF Expression Enhancement Study (2010)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports approximately 30% higher hippocampal BDNF in rats; clinical memory benefit does not follow directly.
Reported population / model
Rat hippocampus
Reported study details
250-500 μg/kg · 24-hour measurement
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Generalized Anxiety Disorder Clinical Trial (2008)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes anxiolysis in GAD/neurasthenia; duration and absence-of-dependence claims require the primary trial's methods and follow-up.
Reported population / model
Human subjects
Reported study details
GAD and neurasthenia · Multi-week treatment
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Memory Consolidation Enhancement (2007)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rats with poorer initial learning reportedly improved after Selank; this is not a human memory-enhancement trial.
Reported population / model
Rat models
Reported study details
Learning paradigms · Head-to-head with Piracetam
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Pep-Pedia: Selank — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 3 min and a peak time of 20 min. Stated attribution: Russian pharmaceutical data. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
13Pep-Pedia: Selank — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12